Literature DB >> 8143052

Outcome of the treatment for sarcoidosis.

G W Hunninghake1, S Gilbert, R Pueringer, C Dayton, C Floerchinger, R Helmers, R Merchant, J Wilson, J Galvin, D Schwartz.   

Abstract

The clinical characteristics and pathology of sarcoidosis are well defined; however, the optimal therapy for this disorder remains unclear. Although patients respond, acutely, to corticosteroid therapy, it is not clear that these agents ultimately alter the natural history of this disease. These observations and that corticosteroids have significant side effects suggest that only patients who will clearly benefit from corticosteroid therapy should be treated. In a prospective study of patients' with sarcoidosis (n = 98), we limited our use of corticosteroids to those patients who had objective evidence of recent deterioration in lung function or serious extrapulmonary disease. All patients with sarcoidosis fulfilling these criteria were treated with corticosteroids. Patients were tapered off corticosteroids after they were treated for 1 yr. Of the 98 study subjects, 91 had not received therapy for the disease and 7 were on therapy before entry into the study. Of the 91 previously untreated patients, 55 were observed without therapy and 36 were treated with corticosteroids. Of those who were observed off therapy, only eight deteriorated. Of these latter patients, six responded and stabilized with the administration of corticosteroids for treatment of the underlying disease, to antibiotics for an associated bronchiectasis, or to diuretics for treatment for congestive heart failure; two were lost to follow-up. None of these six patients deteriorated while receiving corticosteroids. Of the 36 patients who deteriorated and were treated with corticosteroids, 20 remained stable and 16 improved clinically. Of the 37 patients who were eventually tapered off corticosteroids, five deteriorated and required reinitiation of corticosteroid therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143052     DOI: 10.1164/ajrccm.149.4.8143052

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

Review 1.  A clinical approach to the use of methotrexate for sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Ocular involvement in sarcoidosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

3.  Secondary and Infiltrative Cardiomyopathies.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

Review 4.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

5.  Early prediction of sarcoidosis prognosis with HLA typing: a 5 year follow-up study.

Authors:  Ezgi Ozyilmaz; Ozlem Goruroglu Ozturk; Ali Durmaz; Orhan Othman Hasan; Bugra Guzelbaba; Gulsah Seydaoglu; Sedat Kuleci; Ismail Hanta; Eren Erken; Ali Kocabas
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 6.  [Differential therapy of pulmonary fibrosis].

Authors:  P Markart; W Seeger; A Günther
Journal:  Internist (Berl)       Date:  2006-06       Impact factor: 0.743

7.  Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?

Authors:  Elena Bargagli; Carmela Olivieri; Marcella Cintorino; Rosa M Refini; Nicola Bianchi; Antje Prasse; Paola Rottoli
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

Review 8.  Corticosteroids for pulmonary sarcoidosis.

Authors:  N S Paramothayan; T J Lasserson; P W Jones
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 9.  Extrapulmonary manifestations of sarcoidosis.

Authors:  Deepak A Rao; Paul F Dellaripa
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

Review 10.  Obstructive sarcoidosis.

Authors:  Petey Laohaburanakit; Andrew Chan
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.